FDA – Page 58 – Pharma.Tips

Stability failure misinterpreted during ongoing stability – how to avoid repeat observations

Understanding and Addressing Stability Failures Misinterpreted During Ongoing Stability Studies Stability studies are a crucial part of ensuring that pharmaceutical products maintain their quality, safety, and efficacy throughout their shelf…

Waste handling non-compliance during audit – how to withstand inspections

Addressing Non-Compliance in Waste Handling During Audits: An Investigation Framework Waste handling is a critical component of compliance in pharmaceutical manufacturing and can be a frequent point of concern during…

Patent strategy misalignment during partnership discussions – business and regulatory impact analysis

Assessing Patent Strategy Misalignment During Partnership Discussions: A Structured Investigation In the highly regulated pharmaceutical landscape, partnership discussions often lead to significant implications for patent strategies. Misalignment in these discussions…

Safety training gap during audit – how to withstand inspections

Understanding Safety Training Gaps During Audits: Strategies to Improve Inspection Readiness Safety training gaps in pharmaceutical manufacturing can lead to significant compliance risks during regulatory inspections. This article provides a…

IP risks during tech transfer during development – documentation expectations for audits

Understanding Intellectual Property Risks During Development Tech Transfers Technological transfers within the pharmaceutical sector come with a range of potential risks that can impact not only the regulatory standing of…

Contractor safety breach during audit – preventing repeat safety incidents

Investigating Contractor Safety Breaches During Audits to Prevent Future Incidents In high-stakes pharmaceutical environments, contractor safety compliance is paramount. A breach during an audit can reveal gaps that not only…

Data exclusivity lapse risk during partnership discussions – preventing repeat IP exposure

Understanding Data Exclusivity Lapse Risks During Partnership Discussions Data exclusivity is crucial in protecting intellectual property (IP) within the pharmaceutical industry, but lapses in this area can lead to significant…

Permit condition violation during inspection – CAPA escalation pathway

Understanding Permit Condition Violations During Inspections: A CAPA Escalation Guide In the realm of pharmaceutical manufacturing, permit condition violations during regulatory inspections can pose significant risks, leading to increased scrutiny…

Data exclusivity lapse risk during partnership discussions – business and regulatory impact analysis

Analyzing the Risks of Data Exclusivity Lapse During Partnership Discussions As pharmaceutical organizations engage in partnership discussions, the implications of data exclusivity lapses emerge as critical operational concerns. A lapse…

Chemical exposure incident during routine operations – regulatory enforcement risk

Handling Chemical Exposure Incidents During Routine Operations: An Investigation Framework In pharmaceutical manufacturing, the inadvertent exposure to hazardous chemicals during routine operations can pose significant risks not only to personnel…

Patent strategy misalignment during commercialization – CAPA for IP control weaknesses

Identifying and Addressing Patent Strategy Misalignment During Commercialization Patent strategy misalignment during commercialization poses significant risks to pharmaceutical companies, potentially affecting their market position and compliance with regulatory expectations. A…

Contractor safety breach during incident investigation – regulatory enforcement risk

Addressing Contractor Safety Breaches during Incident Investigations: Managing Regulatory Risks In pharmaceutical manufacturing, maintaining rigorous compliance with safety standards is essential not just for regulatory adherence but also for operational…